Introduction
============

Osteosarcoma (OS) is a terrible malignancy characterized by osteoblastic differentiation ([@b1-ol-0-0-8594]). The tumor affects a wide range of age groups ([@b2-ol-0-0-8594]). Recent improvements in the survival of patients with malignant cancers (including OS) may contribute to an increase in the incidence of second primary malignancies (SPMs) ([@b3-ol-0-0-8594]). SPM is a serious problem for the survivors of OS during the follow-up period after treatment ([@b4-ol-0-0-8594]). The relationship between subsequent SPM and OS has been well reported ([@b4-ol-0-0-8594]--[@b7-ol-0-0-8594]), and both hematogenic and solid malignancies tend to occur after OS treatment ([@b7-ol-0-0-8594]). In OS patients, 2-\[^18^F\]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is primarily used for initial cancer staging ([@b8-ol-0-0-8594],[@b9-ol-0-0-8594]), to evaluate the response of neoadjuvant chemotherapy ([@b10-ol-0-0-8594]--[@b12-ol-0-0-8594]), and when recurrence or metastasis is clinically suspected ([@b9-ol-0-0-8594],[@b13-ol-0-0-8594],[@b14-ol-0-0-8594]).

To date, no accurate protocol of postoperative FDG-PET for OS patients has been reported, and there is uncertainty regarding the most appropriate methods for follow-up ([@b15-ol-0-0-8594]--[@b17-ol-0-0-8594]). In addition, no accurate protocol for detecting SPMs after OS treatment exists. SPM can occur anywhere in the body. Early-stage malignancy sometimes manifests no clinical symptoms; in contrast, advanced-stage malignancy generally indicates a poorer prognosis. Therefore, malignancies, including SPM, should be detected as early as the clinicians can. We report a case of a patient with triple primary malignancies (PMs): OS of the jaw, myelodysplastic syndrome (MDS), and adenocarcinoma of the colorectum. After follow-up FDG-PET/computed tomography (CT) was performed, rectal cancer was detected unexpectedly as no clinical symptoms had been observed.

Case report
===========

A 70-year-old man was referred to the Department of Oral and Maxillofacial Surgery, University Hospital of the Ryukyus (Nishihara, Japan) in December 2015, for further evaluation of an oral mass. The patient had a 10-month history of swelling with gradual pain in the gums of his lower jaw. He had no previous malignancies and had never been exposed to ionizing radiation or been administered chemotherapy. He also had no history of family cancer syndrome; however, his mother had a history of kidney cancer. He was a smoker and drinker at the first visit. Written informed consent was obtained from the patient.

Incisional biopsy was performed in his previous clinic, and the lesion had previously been pathologically diagnosed as a spindle cell sarcoma highly suggestive of OS. For details, the histological findings of the initially diagnosed specimens revealed an irregular arrangement of spindle- or oval-shaped tumor cells, accompanying eosinophilic matrix suggesting osteoid formation. Most of the lesions showed mild atypia with rich osteoid formation ([Fig. 1A](#f1-ol-0-0-8594){ref-type="fig"}). Conversely, tumor cells showing high-grade atypia with low osteoid formation existed in part ([Fig. 1B](#f1-ol-0-0-8594){ref-type="fig"}). According to immunohistochemical examination, Ki-67 labeling index was 30--40% ([Fig. 1C](#f1-ol-0-0-8594){ref-type="fig"}). Tumor cells were positively stained for CD56 and were partially positive for smooth muscle actin. The cells were negatively stained for CD34, S100, or bc1-2.

Physical examination showed an elastic-hard, 3.5×2.0-cm mass of the right mandibular premolar gum ([Fig. 2A](#f2-ol-0-0-8594){ref-type="fig"}). No lymphadenopathy was found in the neck region. Panorama X-ray and subsequent contrast-enhanced CT scans from the head to chest and contrast-enhanced magnetic resonance imaging (MRI) of the head and neck were performed. A 3.5×3.0×2.5-cm mass without bone resorption or infiltration was observed. CT scan showed new bone formation on the mandible surface ([Fig. 2B and C](#f2-ol-0-0-8594){ref-type="fig"}). Contrast-enhanced fat-suppression T1-weighted MRI showed a high-signal mass around the mandible bone; however, no invasion to the bone was found ([Fig. 2D](#f2-ol-0-0-8594){ref-type="fig"}). The signal of the bone marrow was considered as a slight bone marrow edema. No other lesion was detected in the neck, bones, or lungs by the above tests. Next, FDG-PET/CT and bone scintigraphy were evaluated to identify the OS staging and any other potential lesions in the whole body. FDG-PET showed increased FDG uptake in the surface of right mandible \[maximum standardized uptake value (SUVmax)=8.82\] ([Fig. 3A](#f3-ol-0-0-8594){ref-type="fig"}). In contrast, no other FDG uptake was seen in the whole body. Bone scintigraphy showed abnormal bone intake on the mandibular surface, but no other sign was found. Based on the above findings, we diagnosed the disease as jaw surface OS without metastasis at the initial presentation. The patient was administered a four-drug preoperative regimen; that is, two cycles of cisplatin and doxorubicin, four cycles of high-dose methotrexate, and additional oral TS-1 for 7 days preoperatively. No preoperative radiotherapy was performed. Second, FDG-PET/CT was performed to evaluate the effect of chemotherapy, and the mass of the lower jaw shrank clinically and radiologically. The FDG uptake in the right mandible was decreased (SUVmax=5.66) ([Fig. 3B](#f3-ol-0-0-8594){ref-type="fig"}). No other indications of lesions were detected in the whole body. Thrombocytopenia, resulting from administration of chemotherapy, was controlled by pegfilgrastim. Subsequently, the patient underwent segmental resection of the right mandible (that is, wide local resection) with reconstruction of a vascularized fibular graft and ipsilateral supraomohyoid neck dissection (April 2016). Histopathological examination revealed 'OS, post-therapeutic state', and the surgical margins were negative. Surgical materials obtained by segmental resection of the right mandible showed a lot of newly formed woven bone attached to the existing mandibular bone, and most of the osteocytes and tumor cells were dead due to chemotherapy. Namely, tumor showed characteristics of bone formation on the surface of mandibular bone ([Fig. 4](#f4-ol-0-0-8594){ref-type="fig"}). No tumor cell was found in the bone marrow. According to these findings, the initially obtained biopsy, clinical and radiological findings, it was suggested that a part of tumor cells showed high-grade atypia, although most of the tumor mass showed abundant bone formation, which arose from the bone surface. Therefore, we considered two possible diagnoses: high-grade OS of the mandible or parosteal OS with partial dedifferentiation to high-grade OS ([@b18-ol-0-0-8594]). However, because of the death of tumor cells due to chemotherapy, we could not determine which diagnosis was correct. There was no indication of metastasis to the lymph nodes. Postoperative chemo/radiotherapy for OS was not performed. Following the surgery, the patient has not shown recurrence or metastasis of OS till the time of this writing.

On the other hand, MDS was found because of a hematoma of the jaw after the surgery, and thrombocytopenia after the surgery was found during the blood testing performed for postoperative follow-up. In spite of platelet transfusion, the thrombocytopenia continued. Therefore, an additional blood test, a bone marrow examination, and a chromosome analysis were performed one month after the surgery (May 2016). Wilms\' tumor gene was positive (74 copies/µg RNA) from the blood test. Histopathological examination of the bone marrow revealed that the marrow was hypercellular, and micromegakaryocytes were abnormally highly expressed in cluster of differentiation 41 staining. The fat-to-cell ratio in the marrow was approximately 2:1, and no OS cells were found. The chromosome analysis revealed a Y-chromosome deficiency. On the basis of the examination results, low-risk MDS (refractory cytopenia of unilineage dysplasia) was diagnosed. The patient was given only a packed red blood cells and platelets transfusion, and no other treatment has been required till the time of this writing.

Eight months after the surgery for OS, the patient complained that his lower jaw felt different. Local recurrence was suspected and contrast-enhanced CT was performed; however, no lesion was found in the head and neck-to-chest region (range of the CT scan). Follow-up third FDG-PET/CT was performed 11 months postoperatively, and abnormal uptake was detected in the rectum (SUVmax=14.58) ([Fig. 5](#f5-ol-0-0-8594){ref-type="fig"}); on the other hand, no other lesion identified by uptake was found in the whole body, including the jaw, neck, bone, or lung. A colorectal tumor was suspected, and subsequent excision by endoscopic mucosal resection was performed (April 2017). Histopathological examination showed an adenocarcinoma and showed that the surgical margin was negative with no vascular invasion. On the other hand, due to the submucosal tumor invasion depth (3,000 µm), the additional radical surgery has been considered. Based on the above, MDS and colorectal cancer were diagnosed after treatment of the jaw cancer. Five months after the resection of the rectal cancer (one year and five months after the jaw OS surgery), the patient was free of any malignant lesion. However, we plan to follow his progress carefully.

Discussion
==========

This case highlights two important points: i) this combination of three PMs (jaw OS, MDS, and colorectal adenocarcinoma) has not been previously reported; and ii) to avoid overlooking solid SPMs, we suggest that FDG-PET should be performed in the long-term follow-up of OS patients.

Firstly, to our knowledge, there also have been no reports of cases involving both hematologic and solid malignancies after OS. We defined our case as involving three PMs by the Warren and Gates criteria reported in 1932 ([@b19-ol-0-0-8594]); that is, each malignancy was distinct and we excluded disease due to metastasis of one of the other malignancies. Using the criteria of Lee *et al* ([@b7-ol-0-0-8594]), we also discriminated between hematologic (leukemia, myeloproliferative disease, myelodysplastic disease, such as MDS, or lymphoma) and solid malignancies (all other malignancies). Thus, our patient had three PMs, including OS and subsequent SPMs involving hematologic and solid tumors. When we then searched PubMed and Google Scholar for English literature between 1932 and 2017, we found no cases describing the same combination of three malignancies, indicating the uniqueness of this case.

Patients with OS tend to develop both hematologic and solid SPMs after treatment ([@b7-ol-0-0-8594]). Compared with cancer-free individuals in the Childhood Cancer Survivor Study, survivors of OS tended to develop SPMs at a greater incidence (the standardized incidence ratio was 4.79) ([@b20-ol-0-0-8594]). Moreover, in a single-institution study, 26 of 1205 patients with OS of their extremities developed SPMs after treatment, which was significantly more frequent compared with the control group (1160 with benign tumors) ([@b21-ol-0-0-8594]). Cancer survivors are generally at risk of SPMs ([@b22-ol-0-0-8594]), with chemotherapy, radiotherapy, and a family history of cancer recognized to contribute to SPMs after OS ([@b21-ol-0-0-8594],[@b23-ol-0-0-8594]--[@b25-ol-0-0-8594]). Our patient had received preoperative chemotherapy and his mother had a history of kidney cancer, but he had no history of family cancer syndrome ([@b25-ol-0-0-8594]). In addition, smoking and alcohol consumption are known independent risk factors of two of the malignancies in our patient ([@b26-ol-0-0-8594]--[@b29-ol-0-0-8594]). Further, old age is a risk factor for cancers such as colorectal cancer ([@b30-ol-0-0-8594]).

Other reports of triple to quintuple PMs involving OS as index malignancy ([@b21-ol-0-0-8594],[@b24-ol-0-0-8594],[@b31-ol-0-0-8594]--[@b33-ol-0-0-8594]) ([Table I](#tI-ol-0-0-8594){ref-type="table"}) have been associated with intervals of 1--26 years between the diagnoses of OS and the SPMs ([@b31-ol-0-0-8594]--[@b33-ol-0-0-8594]), indicating that the occurrence of SPM, particularly solid malignancies, does not decrease over time, after OS treatment. Studies have generally reported that the average interval between OS and subsequent SPMs was 6.0--7.6 years ([@b5-ol-0-0-8594],[@b7-ol-0-0-8594],[@b21-ol-0-0-8594],[@b24-ol-0-0-8594]). Further, in large series, it has been shown that most SPMs occur \>10 years after OS diagnosis, whereas most local or distant recurrences occur ≤5 years, with as few as 5% of patients with OS developing their first local recurrence or distant metastasis greater than or equal to 5 years after initial treatment ([@b20-ol-0-0-8594],[@b34-ol-0-0-8594]). In a smaller study of OS survivors, the cumulative incidences of SPMs at 10, 20, and 30 years were 2.1, 4.0, and 7.4%, respectively, with solid malignancy developing at all times ([@b7-ol-0-0-8594]). Therefore, a long follow-up period is needed after primary treatment for OS to detect both SPMs as well as recurrence, metastasis, or multiple OS ([@b9-ol-0-0-8594],[@b24-ol-0-0-8594],[@b35-ol-0-0-8594],[@b36-ol-0-0-8594]). SPMs after OS can be fatal ([@b6-ol-0-0-8594],[@b7-ol-0-0-8594]), and together with metastasis, chemotherapy response, tumor characteristics, patient characteristics, surgical margins, and toxicity, SPMs are an important prognostic factor ([@b37-ol-0-0-8594]). Indeed, the prognosis is poor once SPMs occur ([@b20-ol-0-0-8594]). In these patients, given that advanced malignancy generally indicates a poorer prognosis, we recommend monitoring to detect SPMs early.

The surface OS of jaw is rare ([@b38-ol-0-0-8594]). Pathologically, we considered two possible histological diagnoses: high-grade surface OS and parosteal OS with partial dedifferentiation to high grade OS. Although the current case could not be clearly diagnosed due to tumor mass degeneration of surgical materials post chemotherapy. According to the findings of osteoid formation with tumor cell atypia showed in [Fig. 1A-C](#f1-ol-0-0-8594){ref-type="fig"}, it was possible that the tumor was high-grade surface OS. However, the incidence of the high-grade surface OS at age 70 years was very unusual. Therefore, we should consider the possibility of parosteal OS with partial dedifferentiation to high-grade OS. Namely, all of the surface OSs of jaw tend to develop approximately 20--30 years old ([@b39-ol-0-0-8594]). Among those, parosteal OS occurs at a relatively higher rate in elderly patients, similar to our patient ([@b38-ol-0-0-8594]). In contrast, high-grade surface OS of jaw is very rare ([@b38-ol-0-0-8594]). Therefore, the current case may be parosteal OS with dedifferentiation of high-grade surface OS ([@b40-ol-0-0-8594]). In OS of the jaw (particularly the surface-type), metastasis is rare but can occur ([@b41-ol-0-0-8594],[@b42-ol-0-0-8594]). The most common site is the lung ([@b41-ol-0-0-8594],[@b42-ol-0-0-8594]). FDG-PET is a useful tool for detecting metastasis of OS ([@b43-ol-0-0-8594]). Conversely, SPM was detected by testing our patient.

Another issue is that FDG-PET should be performed during the long-term follow-up of OS to avoid overlooking solid SPMs. To date, the importance of detecting SPMs during follow-up after OS treatment has not been emphasized. In our case, MDS and colorectal cancer were metachronous according to Moertel\'s definition (i.e., recognized ≥6 months after diagnosis) ([@b44-ol-0-0-8594]). MDS was easily diagnosed because of the hematoma observed after surgery and during the postoperative routine blood test (1 month after resection), which prompted early diagnostic bone marrow aspiration. By contrast, no clinical symptoms of colorectal cancer were present, and the tumor was found incidentally by FDG-PET/CT. Recent improvements in patient survival (including from OS) may lead to increased rates of SPMs ([@b3-ol-0-0-8594]). Further, old age is a risk factor of SPMs such as colorectal cancer ([@b30-ol-0-0-8594]). Therefore, PET/CT studies are recommended to screen for SPMs ([@b22-ol-0-0-8594]).

PET/CT is useful for detecting SPMs in survivors of OS. However, they are not routinely included in OS follow-up protocols because few studies have used them for that purpose ([@b14-ol-0-0-8594],[@b45-ol-0-0-8594]). Indeed, FDG-PET tends to have been reserved for initial cancer staging and for evaluating the response of neoadjuvant chemotherapy ([@b8-ol-0-0-8594]--[@b12-ol-0-0-8594]), even though PET is especially useful after treatment for OS because it is not adversely affected by metal plates or implants ([@b14-ol-0-0-8594]). These scans can also detect three important disease patterns for which whole body examination is needed ([@b5-ol-0-0-8594],[@b7-ol-0-0-8594],[@b21-ol-0-0-8594],[@b24-ol-0-0-8594],[@b35-ol-0-0-8594],[@b46-ol-0-0-8594]): i) recurrence or metastasis ([@b9-ol-0-0-8594],[@b13-ol-0-0-8594],[@b14-ol-0-0-8594]); ii) multiple synchronous or metachronous OS ([@b35-ol-0-0-8594],[@b46-ol-0-0-8594]); and iii) synchronous or metachronous SPMs ([@b5-ol-0-0-8594],[@b7-ol-0-0-8594],[@b21-ol-0-0-8594],[@b24-ol-0-0-8594]). CT and MRI are inadequate because their coverage range is incomplete. Although OS is associated with a high incidence of lung metastases, indicating that chest CT is probably the best screening tool in most cases ([@b14-ol-0-0-8594],[@b47-ol-0-0-8594]), this can fail to identify SPMs at other sites. In the present case, we could not detect the rectal lesion by contrast-enhanced CT that was performed because local recurrence was suspected 8 months after OS treatment.

In daily practice, clinicians check local, regional, and distant sites where OS recurrences typically occur. Further, regarding SPMs for patients with head and neck cancers, they tend to recur locally in the head and neck, esophagus, or lung ([@b48-ol-0-0-8594]). SPMs at other sites (e.g., the colorectum) are relatively rare ([@b49-ol-0-0-8594]). In the current case, the early-stage colorectal SPM was found incidentally by FDG-PET/CT 11 months after treatment. OS is commonly associated with pain or swelling as an early symptom ([@b1-ol-0-0-8594],[@b50-ol-0-0-8594]), and recurrence may be suspected based on clinical symptoms ([@b14-ol-0-0-8594]). However, some SPMs are not associated with clinical symptoms, and it is known that early-stage colorectal cancer can be clinically silent ([@b51-ol-0-0-8594]). In practice, clinicians should consider the benefits and risks of performing FDG-PET/CT for patients after OS treatment. Although we have emphasized the benefits, the following are equally important considerations when choosing FDG-PET/CT: i) the test is generally expensive for patients ([@b47-ol-0-0-8594]); ii) physiological accumulation makes the detection of malignant lesions difficult, especially in the kidney or bladder (the major excretion route of FDG; [Fig. 3](#f3-ol-0-0-8594){ref-type="fig"}); and iii) background activity may obscure the presence of lesions ([@b52-ol-0-0-8594]).

To date, no protocol exists which guides the use of FDG-PET after treatment for OS. Some studies have reported that follow-up PET/CT was useful even when there was no clinical evidence of recurrence or metastasis ([@b14-ol-0-0-8594],[@b53-ol-0-0-8594]--[@b56-ol-0-0-8594]). However, no literature has emphasized the importance of detecting SPMs during follow-up for OS. We recommend that PET/CT should be performed during the follow-up of OS, specifically to detect SPMs.

In conclusion, the specific combination of triple PMs in this case (i.e., jaw OS, MDS, and colorectal adenocarcinoma) has not been reported previously. Based on our research, we recommend that FDG-PET be performed during the long-term follow-up of OS to avoid overlooking solid SPMs. However, our conclusions are based on a single case report, which limits their generalizability. Further cases are needed to help develop a protocol that describes the optimal role of FDG-PET or FDG-PET/CT scans in the identification of hidden synchronous or metachronous SPMs during the follow-up of patients with OS.
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![Histopathological examination revealed irregular arrangement of spindle- or oval-shaped tumor cells. In addition, osteoid lesions with an eosinophilic matrix in those cells were revealed. (A) The majority of the lesions were mild atypia with rich osteoid lesion (original magnification, ×200); (B) Conversely, partially high-grade atypia with few osteoid lesions was observed (original magnification, ×200). (C) Immunohistochemical examination for Ki-67 determined that the labeling index was 30--40% (original magnification, ×40).](ol-15-06-9901-g00){#f1-ol-0-0-8594}

![(A) Physical examination revealed an elastic, hard mass of the right mandibular premolar gum. A 3.5×3.0×2.5-cm mass, without bone resorption or infiltration, was observed. (B and C) CT scan showed novel bone formation on the mandible surface. (D) Contrast-enhanced fat-suppression T1-weighted magnetic resonance imaging revealed the high-signal mass around the mandible bone; however, no invasion to the bone was identified. The signal of the bone marrow was considered as a slight bone marrow edema.](ol-15-06-9901-g01){#f2-ol-0-0-8594}

![FDG-PET/CT and bone scintigraphy were performed to identify the osteosarcoma staging and any other lesions in the whole body. (A) FDG-PET showing increased FDG uptake in the right mandible (SUVmax=8.82; indicated by an arrow). (B) FDG-PET/CT for evaluating the effect of chemotherapy was performed and the mass of the lower jaw shrank radiologically. The FDG uptake in the right mandible was decreased (SUVmax=5.66; indicated by an arrow). FDG-PET, 2-\[^18^F\]-fluoro-2-deoxy-D-glucose positron emission tomography; CT, computed tomography; SUVmax, maximum standardized uptake value.](ol-15-06-9901-g02){#f3-ol-0-0-8594}

![Histopathological examination revealed 'OS, post-therapeutic state', and the surgical margins were negative. A mass with irregular bone formation was observed. Degenerative tissues caused by the chemotherapy were identified in the mass; by contrast, no viable tumor cells were observed. The novel rich bone formation remained in the resected tumor, and the tumor was in contact with the mandibular bone (original magnification, ×200). OS, osteosarcoma.](ol-15-06-9901-g03){#f4-ol-0-0-8594}

![A total of 11 months following the treatment of jaw osteosarcoma, follow-up FDG-PET/computed tomography was performed, and an abnormal uptake was detected in the rectum (SUVmax=14.58; indicated by an arrow). In front of the uptake, physiological accumulation of the bladder was observed (indicated by an arrowhead) as the bladder is the major excretion route for FDG. FDG-PET, 2-\[^18^F\]-fluoro-2-deoxy-D-glucose positron emission tomography; SUVmax, maximum standardized uptake value.](ol-15-06-9901-g04){#f5-ol-0-0-8594}

###### 

Triple to quintuple primary malignancies involving OS as index malignancy.

                                    Type of cancer (age at onset)                                                                                                                                    
  ------------------------ -------- ------------------------------------- -------------------------------- --------------------------------- -------------------------------- ---------------------- ----------------------
  Kubota *et al*, 1997     Male     Non-Hodgkin\'s lymphoma (4Y and 9M)   OS of right femur (7Y and 2M)    MDS (16Y and 4M)                  --                               --                     ([@b31-ol-0-0-8594])
  Bacci *et al*, 2006      NA       OS                                    NA                               NA                                --                               --                     ([@b21-ol-0-0-8594])
  Kimura *et al*, 2001     Female   OS of left femur (9Y)                 Paget Ca. of left breast (19Y)   Paget Ca. of right breast (24Y)   OS of right femur (25Y)          Lung adeno Ca. (26Y)   ([@b32-ol-0-0-8594])
  Yonemoto *et al*, 2004   NA       OS (29Y)                              NA                               Uterine leiomyosarcoma (35Y)      --                               --                     ([@b24-ol-0-0-8594])
  Kousaka *et al*, 2014    Female   OS of left lower leg (15Y)            Tongue squamous cell Ca. (23Y)   Papillary thyroid Ca. (40Y)       Duct Ca. of right breast (41Y)   --                     ([@b33-ol-0-0-8594])
  Present study            Male     OS of jaw (70Y)                       MDS                              Rectal adeno Ca.                  --                               --                     --

OS, osteosarcoma; NA, not applicable; Y, years; M, months; Ca., carcinoma; MDS, myelodysplastic syndrome.
